Dimensional Fund Advisors
VRDN icon

Dimensional Fund Advisors’s Viridian Therapeutics VRDN Stock Holding History

Dimensional Fund Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.6M Buy
1,611,521
+1,081,758
+204% +$17.4M 0.01% 1856
2026
Q1 		$10.4M Sell
529,763
-25,831
-5% -$767K ﹤0.01% 2247
2025
Q4 		$17.3M Sell
555,594
-83,183
-13% -$2.28M ﹤0.01% 2046
2025
Q3 		$13.8M Buy
638,777
+153,079
+32% +$2.76M ﹤0.01% 2175
2025
Q2 		$6.79M Buy
+485,698
New +$6.59M ﹤0.01% 2427
2025
Q1 		– Sell
-55,924
Closed -$1.07M – 3358
2024
Q4 		$1.07M Sell
55,924
-271,156
-83% -$5.9M ﹤0.01% 2898
2024
Q3 		$7.44M Buy
327,080
+219,500
+204% +$3.59M ﹤0.01% 2402
2024
Q2 		$1.4M Buy
107,580
+97,510
+968% +$1.35M ﹤0.01% 2849
2024
Q1 		$176K Hold
10,070
– – ﹤0.01% 3201
2023
Q4 		$219K Hold
10,070
– – ﹤0.01% 3181
2023
Q3 		$154K Hold
10,070
– – ﹤0.01% 3254
2023
Q2 		$240K Sell
10,070
-856
-8% -$22K ﹤0.01% 3209
2023
Q1 		$278K Buy
+10,926
New +$350K ﹤0.01% 3140
2022
Q3 		$234K Hold
11,398
– – ﹤0.01% 3208
2022
Q2 		$132K Buy
+11,398
New +$153K ﹤0.01% 3291
2019
Q4 		– Sell
-13,637
Closed -$150K – 3403
2019
Q3 		$150K Sell
13,637
-294
-2% -$6.5K ﹤0.01% 3306
2019
Q2 		$428K Hold
13,931
– – ﹤0.01% 3213
2019
Q1 		$583K Sell
13,931
-527
-4% -$23.8K ﹤0.01% 3138
2018
Q4 		$657K Buy
14,458
+294
+2% +$17K ﹤0.01% 3102
2018
Q3 		$1.19M Sell
14,164
-153
-1% -$14.4K ﹤0.01% 3034
2018
Q2 		$1.38M Buy
14,317
+3,354
+31% +$355K ﹤0.01% 2962
2018
Q1 		$1.15M Buy
10,963
+6,611
+152% +$718K ﹤0.01% 2976
2017
Q4 		$681K Buy
4,352
+2,670
+159% +$340K ﹤0.01% 3053
2017
Q3 		$231K Buy
+1,682
New +$283K ﹤0.01% 3205

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Dimensional Fund Advisors's VRDN Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Viridian Therapeutics (VRDN) stake by 204% in Q2 2026, buying an estimated $17.4M and bringing the position to 1,611,521 shares worth $29.6M. The position accounts for 0.01% of the portfolio, ranked #1856.

Dimensional Fund Advisors first reported a position in VRDN in Q3 2017 and has held it in 24 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Dimensional Fund Advisors held 1,611,521 shares of Viridian Therapeutics worth $29.6M as of Q2 2026.
  • Dimensional Fund Advisors bought 1,081,758 Viridian Therapeutics shares in Q2 2026, an estimated $17.4M.
  • Viridian Therapeutics made up 0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #1856 holding.
  • Dimensional Fund Advisors first reported a position in Viridian Therapeutics in Q3 2017 and has held it in 24 quarters since.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.